UnitedHealth Group Incorporated (UNH) Stock Price & How to Invest

UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.

The October 2026 picture is a company rebuilding margins on a revenue base of about $450 billion over the trailing twelve months. Revenue has been flat at around $112-113 billion a quarter through 2026 (the September quarter's $112.7 billion was down about 0.4% year on year), while profits have recovered from a very weak end to 2025, when fourth-quarter net income was close to zero. For the quarter ended September 30, 2026, UnitedHealth reported EPS of $4.69 against a $4.14 consensus and net income of about $4.1 billion, and it raised its full-year outlook to at least $19.50 of diluted EPS and more than $17.65 billion of net earnings attributable to common shareholders. Earlier in 2026, EPS of $7.23 and $6.38 beat consensus of $6.60 and $4.92. The stock, which traded as low as about $255.97 over the past 52 weeks, closed near $401.67 on October 16, 2026, still below its 52-week high of about $461.62. Operating margin over the trailing year is about 5.8% and the net margin about 3.5%, thin even by managed-care standards and well below where they stood before the medical-cost surge.

UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. The 2026 recovery also raises the bar: at roughly 17x forward earnings the stock now prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor.

25 analysts publish price targets on UNH, averaging $477.04 against a $401.43 price as of October 2026, or +18.8%. The published targets run from $380.00 to $529.00, a moderate spread, and the ratings split 22 buy, 4 hold, 0 sell. Over the last six months there have been 7 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full UNH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on UnitedHealth Group Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Optum growth engine. Optum, especially Optum Health (value-based care delivery) and Optum Rx (pharmacy benefits), grows faster than the insurance business and carries higher returns on capital. The most optimistic published target, $529.00, assumes this works close to its best case.

The case against. UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. The most pessimistic target, $380.00, is roughly what UNH is worth if this bites instead.

Read the full bull and bear case on UNH, including what would have to change to break either one. Walnut is not an investment adviser.

No. UnitedHealth Group Incorporated (UNH) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see UnitedHealth Group Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year
• Operating margin: ~5.8% (net margin ~3.5%)
• Net income (TTM): ~$15.9 billion (sensitive to medical costs)
• EPS: ~$15.55 trailing; Q3 2026 $4.69 vs $4.14 consensus
• 2026 outlook: Raised to at least $19.50 diluted EPS (October 2026)
• P/E: ~25.8x trailing, ~17.3x forward
• Dividend yield: ~2.3% (~$9.28 per share a year)
• Market cap: ~$361 billion at ~$401.67 per share (Oct 16, 2026)

The trailing P/E of about 26x is inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 17x, closer to its historical range. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. The stock has recovered a large part of its 2025 decline, which leaves less of a discount for regulatory and cost risk than a year ago.

If you want UNH exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses UNH naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to UNH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get UNH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (UDOW, SCHD, DIA), which spreads the position across many companies. Or build it into a focused thematic portfolio, so UNH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where UNH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

UnitedHealth Group (UNH) combines the largest US insurance book with Optum's faster-growing, higher-return services arm, giving it scale and a deep claims-data advantage offset by medical-cost inflation, PBM scrutiny, and political risk. In a portfolio it behaves like a large-cap, dividend-paying healthcare anchor whose volatility tracks Medicare Advantage utilization and regulatory headlines. In 2026 the story has been a recovery from a deep 2025 drawdown: four straight quarters at or above EPS consensus and a guidance raise in October.

Whether UNH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is UNH a buy or a sell?, and where the stock could go from here in the UNH stock forecast.

For income investors, whether UNH pays a dividend and how the payout looks is covered in does UNH pay a dividend? And to weigh UNH against a peer, read the full side-by-side comparisons: UNH vs JNJ and UNH vs COST.